?Diabetes Care Drugs Market Evolution Analysis by Industry Size, Share, Advancement Strategies, Business Demand and Forecast till 2019-2024

Diabetes

Report Titled: “Global Diabetes Care Drugs Market – Growth, Trends and Forecast (2019 – 2024)

The Research Report on “Diabetes Care Drugs Market” 2019 report includes every aspect of the Diabetes Care Drugs industry along with the progress performance. Diabetes Care Drugs Market report presents an analysis of market size, share, and growth, trends, and price structure, statistical and detailed data of the Diabetes Care Drugs industry. Additionally, Diabetes Care Drugs Market 2019 research report offers key analysis on the industry status of the Diabetes Care Drugs producers with market size, growth, share, trends as well as business price structure.

The Diabetes Care Drugs Market report is a professional and detailed study on the Diabetes Care Drugs business. Diabetes Care Drugs market to predict future market directions between the forecast periods from 2019 to 2024 providing you with vital data for your business decisions.

Get a Sample Copy of the Report – https://www.industryresearch.co/enquiry/request-sample/14244205

Scope of the Report:

  • The global diabetes care drugs market is segmented by category (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs), by segment (basal or long-acting, bolus or fast-acting, traditional human insulin drugs, insulin biosimilars, GLP-1 receptor agonists, alpha-glucosidase inhibitors, DPP-4 inhibitors, and SGLT-2 inhibitors) and by geography.

    Market Overview:

  • – The market size, in 2017, for the global diabetes drugs market was registered to be USD 67.5 billion, and the market is expected to record a CAGR of 5.65% during the forecast period, 2019-2024.
  • – North America dominates the market, followed by Asia-Pacific.
  • – Diabetes or diabetes mellitus, describes a group of metabolic diseases in which the person has high blood glucose (blood sugar), either because insulin production is inadequate or one does not produce insulin (known as Type 1 diabetes), or because the body’s cells do not respond properly to insulin (known as Type 2 diabetes), or both.
  • – Approximately 10% of all diabetes cases are Type 1, and approximately 90% of all cases of diabetes worldwide are of Type 2.

    Diabetes Care Drugs Report Also Covers Offer for New Project Includes:

    • Market Entry Strategies
    • Countermeasures of Economic Impact
    • Marketing Channels
    • Feasibility Studies of New Project Investment
    • Research Conclusions of the Diabetes Care Drugs Industry

    The report provides key statistics on the market status of the Diabetes Care Drugs Market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Diabetes Care Drugs.

    Enquire Before Purchasing this Report – https://www.industryresearch.co/enquiry/pre-order-enquiry/14244205

    Diabetes Care Drugs Market Report Also Covers Marketing Strategy Analysis, Top Manufacturers:

  • Novo Nordisk
  • Sanofi
  • Eli Lilly
  • Takeda
  • Pfizer
  • Janssen Pharmaceuticals
  • Astellas
  • Boehringer Ingelheim
  • Merck and Co.
  • AstraZeneca
  • Bristol Myers Squibb
  • Novartis

    Key Market Trends:

    Rising Prevalence of Diabetes

    – As per a WHO report, the global prevalence of diabetes among adults of over 18 years had accelerated from about 4.7%, in 1980, to over 8.5%, in 2014.
    – Diabetes prevalence has been rising rapidly in the middle- and low-income countries. In 2015, about 1.6 million deaths were directly associated with diabetes, which was around 2.2 million in 2012.
    – Almost half of all deaths attributable to high blood glucose occur before the age of 70 years. WHO projects that diabetes is likely to be the seventh leading cause of death by 2030.
    – Statistics prove that one in ten individuals in the world has diabetes and a rise in this trend is expected to take the situation to one in three by 2050 (according to the Center for Disease Control and Prevention).
    – The growing prevalence of diabetes is the major driver for the global diabetes care drugs market. Additionally, rising awareness regarding diabetes care, growing prevalence of obesity, and technological advancements are further driving the market.

    The United States Leads the Diabetes Drugs Market in North America

    – In 2017, the US diabetes drugs market held the largest market share in North America, due to the presence of a high-quality healthcare system and increasing prevalence of diabetes in the region.
    – In the Asia-Pacific region, China and India have been identified as potential emerging markets, due to the rising diabetic population in this region.

    Purchase this Report (Price 6000 USD for Single User License) – https://www.industryresearch.co/purchase/14244205

    Detailed TOC of Diabetes Care Drugs Market Report are:

    1 INTRODUCTION
    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study

    2 RESEARCH METHODOLOGY

    3 EXECUTIVE SUMMARY

    4 MARKET DYNAMICS
    4.1 Market Overview
    4.2 Drivers
    4.3 Restraints
    4.4 Porter’s Five Forces Analysis
    4.4.1 Bargaining Power of Suppliers
    4.4.2 Bargaining Power of Consumers
    4.4.3 Threat of New Entrants
    4.4.4 Threat of Substitute Products and Services
    4.4.5 Intensity of Competitive Rivalry

    5 MARKET SEGMENTATION
    5.1 By Drug
    5.1.1 Oral Anti-diabetic drugs (Value and Volume 2012-2024)
    5.1.1.1 Biguanides
    5.1.1.1.1 Metformin
    5.1.1.2 Alpha-Glucosidase Inhibitors
    5.1.1.3 Dopamine -D2 Receptor Agonist
    5.1.1.3.1 Cycloset (Bromocriptin)
    5.1.1.4 Sodium-glucose Cotransport -2 (SGLT-2) Inhibitors
    5.1.1.4.1 Invokana (Canagliflozin)
    5.1.1.4.2 Jardiance (Empagliflozin)
    5.1.1.4.3 Farxiga/Forxiga (Dapagliflozin)
    5.1.1.4.4 Suglat (Ipragliflozin)
    5.1.1.5 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
    5.1.1.5.1 Januvia (Sitagliptin)
    5.1.1.5.2 Onglyza (Saxagliptin)
    5.1.1.5.3 Tradjenta (Linagliptin)
    5.1.1.5.4 Vipidia/Nesina (Alogliptin)
    5.1.1.5.5 Galvus (Vildagliptin)
    5.1.1.6 Sulfonylureas
    5.1.1.7 Meglitinides
    5.1.2 Insulins (Value and Volume 2012-2024)
    5.1.2.1 Basal or Long-acting Insulin
    5.1.2.1.1 Lantus (Insulin Glargine)
    5.1.2.1.2 Levemir (Insulin Detemir)
    5.1.2.1.3 Toujeo (Insulin Glargine)
    5.1.2.1.4 Tresiba (Insulin Degludec)
    5.1.2.1.5 Basaglar (Insulin Glargine)
    5.1.2.2 Bolus or Fast-acting Insulin
    5.1.2.2.1 NovoRapid/Novolog (Insulin Aspart)
    5.1.2.2.2 Humalog (Insulin Lispro)
    5.1.2.2.3 Apidra (Insulin Glulisine)
    5.1.2.3 Traditional Human Insulin
    5.1.2.3.1 Novolin/Actrapid/Insulatard
    5.1.2.3.2 Humulin
    5.1.2.3.3 Insuman
    5.1.2.4 Biosimilar Insulin
    5.1.2.4.1 Insulin Glargine Biosimilars
    5.1.2.4.2 Human Insulin Biosimilars
    5.1.3 Non-insulin Injectable drugs (Value and Volume 2012-2024)
    5.1.3.1 GLP-1 Receptor Agonists
    5.1.3.1.1 Victoza (Liraglutide)
    5.1.3.1.2 Byetta (Exenatide)
    5.1.3.1.3 Bydureon (Exenatide)
    5.1.3.1.4 Trulicity (Dulaglutide)
    5.1.3.1.5 Lyxumia (Lixisenatide)
    5.1.3.2 Amylin Analogue
    5.1.3.2.1 Symlin (Pramlintide)
    5.1.4 Combination Drugs
    5.1.4.1 Combination Insulin
    5.1.4.1.1 NovoMix (Biphasic Insulin Aspart)
    5.1.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
    5.1.4.1.3 Xultophy (Insulin Degludec and Liraglutide)
    5.1.4.2 Oral Combination
    5.1.4.2.1 Janumet (Sitagliptin and Metformin HCl)
    5.2 Geography
    5.2.1 North America
    5.2.1.1 United States (Value and Volume 2012-2024)
    5.2.1.1.1 Oral Anti-diabetic Drugs
    5.2.1.1.2 Insulin
    5.2.1.1.3 Non-Insulin Injectable Drugs
    5.2.1.1.4 Combination Drugs
    5.2.1.1.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.1.2 Canada (Value and Volume 2012-2024)
    5.2.1.2.1 Oral Anti-diabetic Drugs
    5.2.1.2.2 Insulin
    5.2.1.2.3 Non-Insulin Injectable Drugs
    5.2.1.2.4 Combination Drugs
    5.2.1.2.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.1.3 Rest of North America (Value and Volume 2012-2024)
    5.2.1.3.1 Oral Anti-diabetic Drugs
    5.2.1.3.2 Insulin
    5.2.1.3.3 Non-Insulin Injectable Drugs
    5.2.1.3.4 Combination Drugs
    5.2.1.3.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.2 Europe
    5.2.2.1 France (Value and Volume 2012-2024)
    5.2.2.1.1 Oral Anti-diabetic Drugs
    5.2.2.1.2 Insulin
    5.2.2.1.3 Non-Insulin Injectable Drugs
    5.2.2.1.4 Combination Drugs
    5.2.2.1.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.2.2 Germany (Value and Volume 2012-2024)
    5.2.2.2.1 Oral Anti-diabetic Drugs
    5.2.2.2.2 Insulin
    5.2.2.2.3 Non-Insulin Injectable Drugs
    5.2.2.2.4 Combination Drugs
    5.2.2.2.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.2.3 Italy (Value and Volume 2012-2024)
    5.2.2.3.1 Oral Anti-diabetic Drugs
    5.2.2.3.2 Insulin
    5.2.2.3.3 Non-Insulin Injectable Drugs
    5.2.2.3.4 Combination Drugs
    5.2.2.3.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.2.4 Spain (Value and Volume 2012-2024)
    5.2.2.4.1 Oral Anti-diabetic Drugs
    5.2.2.4.2 Insulin
    5.2.2.4.3 Non-Insulin Injectable Drugs
    5.2.2.4.4 Combination Drugs
    5.2.2.4.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.2.5 United Kingdom (Value and Volume 2012-2024)
    5.2.2.5.1 Oral Anti-diabetic Drugs
    5.2.2.5.2 Insulin
    5.2.2.5.3 Non-Insulin Injectable Drugs
    5.2.2.5.4 Combination Drugs
    5.2.2.5.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.2.6 Russia (Value and Volume 2012-2024)
    5.2.2.6.1 Oral Anti-diabetic Drugs
    5.2.2.6.2 Insulin
    5.2.2.6.3 Non-Insulin Injectable Drugs
    5.2.2.6.4 Combination Drugs
    5.2.2.6.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.2.7 Rest of Europe (Value and Volume 2012-2024)
    5.2.2.7.1 Oral Anti-diabetic Drugs
    5.2.2.7.2 Insulin
    5.2.2.7.3 Non-Insulin Injectable Drugs
    5.2.2.7.4 Combination Drugs
    5.2.2.7.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.3 Latin America
    5.2.3.1 Mexico (Value and Volume 2012-2024)
    5.2.3.1.1 Oral Anti-diabetic Drugs
    5.2.3.1.2 Insulin
    5.2.3.1.3 Non-Insulin Injectable Drugs
    5.2.3.1.4 Combination Drugs
    5.2.3.1.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.3.2 Brazil (Value and Volume 2012-2024)
    5.2.3.2.1 Oral Anti-diabetic Drugs
    5.2.3.2.2 Insulin
    5.2.3.2.3 Non-Insulin Injectable Drugs
    5.2.3.2.4 Combination Drugs
    5.2.3.2.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.3.3 Rest of Latin America (Value and Volume 2012-2024)
    5.2.3.3.1 Oral Anti-diabetic Drugs
    5.2.3.3.2 Insulin
    5.2.3.3.3 Non-Insulin Injectable Drugs
    5.2.3.3.4 Combination Drugs
    5.2.3.3.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.4 Asia-Pacific
    5.2.4.1 Japan (Value and Volume 2012-2024)
    5.2.4.1.1 Oral Anti-diabetic Drugs
    5.2.4.1.2 Insulin
    5.2.4.1.3 Non-Insulin Injectable Drugs
    5.2.4.1.4 Combination Drugs
    5.2.4.1.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.4.2 South Korea (Value and Volume 2012-2024)
    5.2.4.2.1 Oral Anti-diabetic Drugs
    5.2.4.2.2 Insulin
    5.2.4.2.3 Non-Insulin Injectable Drugs
    5.2.4.2.4 Combination Drugs
    5.2.4.2.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.4.3 China (Value and Volume 2012-2024)
    5.2.4.3.1 Oral Anti-diabetic Drugs
    5.2.4.3.2 Insulin
    5.2.4.3.3 Non-Insulin Injectable Drugs
    5.2.4.3.4 Combination Drugs
    5.2.4.3.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.4.4 India (Value and Volume 2012-2024)
    5.2.4.4.1 Oral Anti-diabetic Drugs
    5.2.4.4.2 Insulin
    5.2.4.4.3 Non-Insulin Injectable Drugs
    5.2.4.4.4 Combination Drugs
    5.2.4.4.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.4.5 Australia (Value and Volume 2012-2024)
    5.2.4.5.1 Oral Anti-diabetic Drugs
    5.2.4.5.2 Insulin
    5.2.4.5.3 Non-Insulin Injectable Drugs
    5.2.4.5.4 Combination Drugs
    5.2.4.5.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.4.6 Vietnam (Value and Volume 2012-2024)
    5.2.4.6.1 Oral Anti-diabetic Drugs
    5.2.4.6.2 Insulin
    5.2.4.6.3 Non-Insulin Injectable Drugs
    5.2.4.6.4 Combination Drugs
    5.2.4.6.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.4.7 Malaysia (Value and Volume 2012-2024)
    5.2.4.7.1 Oral Anti-diabetic Drugs
    5.2.4.7.2 Insulin
    5.2.4.7.3 Non-Insulin Injectable Drugs
    5.2.4.7.4 Combination Drugs
    5.2.4.7.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.4.8 Indonesia (Value and Volume 2012-2024)
    5.2.4.8.1 Oral Anti-diabetic Drugs
    5.2.4.8.2 Insulin
    5.2.4.8.3 Non-Insulin Injectable Drugs
    5.2.4.8.4 Combination Drugs
    5.2.4.8.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.4.9 Philippines (Value and Volume 2012-2024)
    5.2.4.9.1 Oral Anti-diabetic Drugs
    5.2.4.9.2 Insulin
    5.2.4.9.3 Non-Insulin Injectable Drugs
    5.2.4.9.4 Combination Drugs
    5.2.4.9.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.4.10 Thailand (Value and Volume 2012-2024)
    5.2.4.10.1 Oral Anti-diabetic Drugs
    5.2.4.10.2 Insulin
    5.2.4.10.3 Non-Insulin Injectable Drugs
    5.2.4.10.4 Combination Drugs
    5.2.4.10.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.4.11 Rest of Asia-Pacific (Value and Volume 2012-2024)
    5.2.4.11.1 Oral Anti-diabetic Drugs
    5.2.4.11.2 Insulin
    5.2.4.11.3 Non-Insulin Injectable Drugs
    5.2.4.11.4 Combination Drugs
    5.2.4.11.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.5 Middle East & Africa
    5.2.5.1 Saudi Arabia (Value and Volume 2012-2024)
    5.2.5.1.1 Oral Anti-diabetic Drugs
    5.2.5.1.2 Insulin
    5.2.5.1.3 Non-Insulin Injectable Drugs
    5.2.5.1.4 Combination Drugs
    5.2.5.1.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.5.2 Iran (Value and Volume 2012-2024)
    5.2.5.2.1 Oral Anti-diabetic Drugs
    5.2.5.2.2 Insulin
    5.2.5.2.3 Non-Insulin Injectable Drugs
    5.2.5.2.4 Combination Drugs
    5.2.5.2.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.5.3 Egypt (Value and Volume 2012-2024)
    5.2.5.3.1 Oral Anti-diabetic Drugs
    5.2.5.3.2 Insulin
    5.2.5.3.3 Non-Insulin Injectable Drugs
    5.2.5.3.4 Combination Drugs
    5.2.5.3.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.5.4 Oman (Value and Volume 2012-2024)
    5.2.5.4.1 Oral Anti-diabetic Drugs
    5.2.5.4.2 Insulin
    5.2.5.4.3 Non-Insulin Injectable Drugs
    5.2.5.4.4 Combination Drugs
    5.2.5.4.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.5.5 South Africa (Value and Volume 2012-2024)
    5.2.5.5.1 Oral Anti-diabetic Drugs
    5.2.5.5.2 Insulin
    5.2.5.5.3 Non-Insulin Injectable Drugs
    5.2.5.5.4 Combination Drugs
    5.2.5.5.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.5.6 Rest of Middle & Africa (Value and Volume 2012-2024)
    5.2.5.6.1 Oral Anti-diabetic Drugs
    5.2.5.6.2 Insulin
    5.2.5.6.3 Non-Insulin Injectable Drugs
    5.2.5.6.4 Combination Drugs
    5.2.5.6.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)

    6 MARKET INDICATORS
    6.1 Type 1 Diabetes Population (2012-2024)
    6.2 Type 2 Diabetes Population (2012-2024)

    7 COMPETITIVE LANDSCAPE
    7.1 COMPANY PROFILES
    7.1.1 Novo Nordisk
    7.1.2 Sanofi
    7.1.3 Eli Lilly
    7.1.4 Takeda
    7.1.5 Pfizer
    7.1.6 Janssen Pharmaceuticals
    7.1.7 Astellas
    7.1.8 Boehringer Ingelheim
    7.1.9 Merck and Co.
    7.1.10 AstraZeneca
    7.1.11 Bristol Myers Squibb
    7.1.12 Novartis
    7.2 COMPANY SHARE ANALYSIS
    7.2.1 Novo Nordisk
    7.2.2 Sanofi
    7.2.3 Eli Lilly
    7.2.4 AstraZeneca
    7.2.5 Astellas
    7.2.6 Janssen Pharmaceuticals
    7.2.7 Merck and Co.
    7.2.8 Others

    8 MARKET OPPORTUNITIES AND FUTURE TRENDS

     

    Contact Us:

    Name: Ajay More

    Phone: US +14242530807/ UK +44 20 3239 8187

    Email: [email protected]

    Our Other Reports:

    Access Controls Market 2019 Global Industry Trends, Statistics, Competition Strategies, Revenue Analysis, Key Players, Regional Analysis by Forecast to 2025

    Global Communication Processors Market 2019: Comprehensive Insight by Growth Rate, Global Trends, Industry Status, Key Players Forecast till 2025

    Smart Wristband Market 2019 Size, Global Trends, Comprehensive Research Study, Development Status, Opportunities, Future Plans, Competitive Landscape and Growth by Forecast 2025